作者: Shuang Hu , Charles Preston Neff , Dipu Mohan Kumar , Yuichiro Habu , Sarah R. Akkina
DOI: 10.1016/J.VIROL.2016.11.013
关键词:
摘要: While HIV-2 is a causative agent for AIDS in addition to the better studied HIV-1, there currently no suitable animal model experimental studies infection and evaluating promising drugs vivo. Here we evaluated humanized mice their susceptibility tested single-pill three drug formulation of anti-retrovirals (NRTIs abacavir lamivudine, integrase inhibitor dolutegravir) (trade name, TriumeqR). Our results showed that hu-mice are susceptible showing persistent viremia CD4 T cell loss, key hallmarks pathogenesis. Oral treatment led full viral suppression protection from depletion. Cessation therapy resulted rebound loss. These proof-of-concept establish utility pathogenesis more detail future, testing novel therapies providing pre-clinical efficacy data combination treat infections.